



Incyte Corporation
1801 Augustine Cut-Off
Wilmington, DE 19803

Tel 302.498.6700
Web www.incyte.com

Subject:	Missing trial results justification
EudraCT No.:	2017-002773-19
IMP:	INCB039110 - Itacitinib (as adipate) 100 mg sustained-release tablets and IMBRUVICA (Ibrutinib)
Protocol No.:	INCB 39110-206
Protocol Title:	An Open-Label Phase 1/2 Study of INCB039110 in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sponsor:	Incyte Corporation

Incyte hereby informs that the trial results for the above-mentioned study are missing because no subjects were recruited in the participating EU and UK countries. Indeed, the clinical trial application was approved in Belgium, France, Netherlands, and the UK and subsequently withdrawn before any sites in Belgium, France, Netherlands, and the UK were initiated and recruited subjects.